Philip Astley-Sparke

CEO & Chairman

Philip Astley-Sparke is Chief Executive Officer, Director and co-founder of Replimune. Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Philip relocated the Company from the UK to the US in 2005 before Biovex was acquired by Amgen for up to $1bn ...

Roles at Replimune

  • CEO & Chairman

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.